Office Administrator

Save to Favorites

About Chris Elliott Fund dba EndBrainCancer Initiative

Location:

16150 NE 85th St, #201, Redmond, WA 98052, US

Mission Statement

The EndBrainCancer Initiative | Chris Elliott Fund is dedicated to ensuring that all patients diagnosed with brain cancer, a brain tumor, or metastatic disease to the brain have equal access to advanced diagnostics, treatments, specialists and clinical trial participation. We believe that IMMEDIATE ACCESS to these options provides this patient community with the best HOPE for survival and sustained quality of life. We partner with industry, patients, researchers, advocacy groups, medical teams, hospital networks and others to educate patients and their caregivers so they can have empowered conversations with medical teams.

Description

The End Brain Cancer Initiative (EBCI), formerly the Chris Elliott Fund, has spent over 20 years working to support and guide patients and their caregivers through their medical journey after a diagnosis of Brain Cancer, a Brain Tumor, or Metastatic Disease to the Brain.

Glioblastoma (GBM) is the most common and aggressive form of adult brain cancer. Diagnosed patients have an average prognosis of 12-15 months with the current Standard of Care. Only about 5% of GBM patients will survive more than 5 years, a statistic that has not moved in over 50 years. We aim to educate patients and their caregivers on all forms of available treatment, including clinical trials. We believe that a fully informed patient can have a stronger conversation with their medical team and thereby gain access to better treatments. We hope that this will lead to improved survivorship and a better quality of life overall.

EBCI supports their mission through 3 service programs:

• Patient Disease Education, Awareness and Outreach programs and events
• Advocacy and Access Initiatives
• "Direct Connect" Service Program

Our Patient Disease Education programs occur several times per year, sharing information on the latest developments in treatments, both drug and device, and in advanced diagnostic tools through our website, disease education materials, social media/digital services, speaking opportunities, and customized 1:1 virtual/in person meetings with patients/caregivers.